CD274 and hepatocellular carcinoma: As combination therapies that pair PD-1/PD-L1 or CTLA-4 blockade with metabolic modulators continue to be explored, a personalized approach to targeting both tumor metabolism and immune evasion may emerge as a new standard for advanced HCC (Table 2).